Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)
Jaguar Health announced preliminary discussions with the FDA to evaluate a Breakthrough Therapy Designation for crofelemer to treat pediatric Microvillus Inclusion Disease. The filing is supported by data from two patients showing meaningful reductions in weekly parenteral support needs, with a pivotal randomized trial having completed enrollment.
Key figures
- Drug Name
- crofelemer
- Phase Of Trial
- pivotal randomized double-blind placebo-controlled
- Patients in poc
- 2
- Current patient penetration
- 4% of estimated living pediatric MVID patients
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.